A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

• Status: Terminated
• Trial end date: 2015-12-24
• Target enrollment: 0
• Participant gender: Female

Summary

This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel combination in patients with advanced breast cancer. Preliminary information about the efficacy of the combination will also be collected.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Docetaxel

Criteria

Inclusion Criteria:

• Diagnosis of breast cancer with evidence of a) metastatic or b) locally recurrent/advanced disease.

Exclusion Criteria:

• Prior treatment with a gamma secretase inhibitors or other Notch signaling inhibitors.